Subtype-Specific Mechanisms of Treatment Resistance and Relapse in Diffuse Large B Cell Lymphoma (DLBCL)

Janek S. Walker; Kerstin Wenzl; Joseph P. Novak; Matthew E. Stokes; Melissa A. Hopper; Abigail R. Dropik; Miranda S. Laverty; Allison M. Bock; Vivekananda Sarangi; Maria Ortiz; Nicholas Stong; Chris Huang; Matthew J. Maurer; Brian K. Link; Stephen M. Ansell; Thomas M. Habermann; Thomas E. Witzig; Rebecca L. King; Grzegorz S. Nowakowski; James R. Cerhan; Anita K. Gandhi; Anne J. Novak

doi:10.1182/blood-2024-208182

Introduction: Diffuse large B cell lymphoma (DLBCL) patients experience favorable outcomes following frontline immunochemotherapy, however, 30-40% of patients will exhibit primary refractory disease or relapse (rrDLBCL). Recent studies have expanded upon well-defined characteristics of newly diagnosed DLBCL (ndDLBCL) to elucidate genomic landscapes underlying rrDLBCL; yet, high-throughput examination of resistance and relapse mechanisms within rrDLBCL subtypes, including the newly defined dark zone signature (DZsig) addition to cell of origin (COO), have yet to be described. To expand upon the current tumor etiology and define subtype-specific driving mechanisms, we describe a multi-omic analysis leveraging clinical and biologic variables in rrDLBCL. Methods: Tumor biopsies (N=228) collected at the time of relapse were obtained from n=85 participants in the Mayo Clinic/University of Iowa Lymphoma Molecular Epidemiology Resource (MER), n=73 in the Mayo Clinic Biobank, and n=38 from CC-122-DLBCL-001 or n=32 CC-122-ST-001 trials. Tumor samples were analyzed by WES (n=158) or WGS (n=70) and by RNAseq (n=145). Comparative analysis against ndDLBCL MER samples (N=444) utilized WES (n=404) and RNAseq (n=321). Chi Square or Fisher's exact test was used for enrichment analysis of categorical variables, while Wilcoxon or Kruskal-Wallis test was used for continuous variables. Results: rrDLBCL samples were enriched for ABC (46% vs 33% in ndDLBCL, p=0.01), and fewer GCB (27% vs 40%, p=0.006). Amongst rrDLBCL patients, variance in overall survival (from time of original diagnosis; log-rank p=0.001) was observed between COO subtypes, with poor outcomes in patients with DZsig (median 15.0 mo) and GCB (36.5 mo) compared to ABC tumors (74.4 mo). Patients with progression or relapse within 6 months featured a more even COO distribution (ABC - 22%, GCB - 34%, DZsig - 28%) than patients with early (6-24 mo; 51%, 22%, 22%) or late relapses (>24 mo; 62%, 19%, 4%), which were predominantly ABC. Comparing mutation frequency within subtypes, rrDLBCL GCB tumors were enriched for B2M (41% vs 15% in ndDLBCL, p=0.002), EP300 (19% vs 7%, p=0.059), CIITA (19% vs 5%, p=0.02), PRKCB (11% vs 2%, p=0.035), CD79B (11% vs 0%, p=0.004), and CD83 (8% vs 1%, p=0.049) mutations, and CNV events including gains at 8q24.21 (MYC locus; 48% vs 14%, p<0.001) and 18q21.33 (BCL2, TCF4 locus; 36% vs 15%, p=0.021), and losses at 17p13.1 (TP53 locus; 40% vs 19%, p=0.035). rrDLBCL DZsig tumors featured enrichment for BCL6 (22% vs 3%, p=0.025), and SPEN (17% vs 3%, p=0.062) mutations and 2q22.2 losses (LRP1B locus; 20% vs 0%, p=0.019). Despite differential mutation and CNV profiles, gene expression analysis revealed minimal variance within COO subtypes in rrDLBCL and ndDLBCL, however upregulation of lymphoma driving genes including MYBPC2 (LogFC=1.68, FDR<0.001), MYOM2 (LogFC=1.33, FDR=0.007), MYC (LogFC=0.61, FDR=0.04), and CELSR2 (LogFC=0.53, FDR=0.02) were observed in ABC rrDLBCL. Increased frequency of LymphGen classifier A53 was observed in ABC (43% vs 17%, p=0.005) and GCB (40% vs 14%, p=0.009) rrDLBCL. Using CIBERSORTx to infer lymphoma microenvironment (LME) cell type abundance, an LME-depleted class was evident in rrDLBCL tumors, including reduction of CD8+ T cells (effect size (r)=-0.78, p<0.001) and T follicular helper cells (r=-0.48, p=0.012) in GCB rrDLBCL and reduction of T follicular helper cells (r=-0.43, p=0.023) and Tregs (r=-0.32, p=0.065) in DZsig rrDLBCL. Significance: We present an update to the genomic landscape of rrDLBCL, highlighting GCB and DZsig tumors with differential biology and advanced clinical course. Our data supports increased implementation of sequencing efforts in rrDLBCL to more broadly evaluate relapse mechanisms, with optimism that a more detailed understanding of r/r disease may guide trials for targeted treatment strategies. For example, rrDLBCL patients may be strong candidates for MYC pathway targeting agents (BETi), or a Lenalidomide-based regimen (R2 or Tafa-Len), as Lenalidomide has been shown to reprogram the LME via PD-L1 expression in addition to downregulation of MYC and MYC target genes. Or, due to enrichment of variants affecting anti-apoptotic proteins including BCL6 or BCL2 in DZsig and GCB rrDLBCL, a venetoclax-based therapeutic may be considered. Further targeted strategies should be considered as development of a more personalized approach remains an unmet need. Wenzl:Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company, Current holder of stock options in a privately-held company. Stokes:Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company, Current holder of stock options in a privately-held company. Ortiz:Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company, Current holder of stock options in a privately-held company. Stong:Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Huang:Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Maurer:BMS: Consultancy, Research Funding; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; GenMab: Research Funding; Roche/Genentech: Research Funding. Link:Genentech: Research Funding. Ansell:SeaGen: Research Funding; Takeda: Research Funding; Regeneron Pharmaceuticals, Inc.: Research Funding; Bristol Myers Squibb: Research Funding; ADC Therapeutics: Research Funding; Pfizer: Research Funding; Affimed: Membership on an entity's Board of Directors or advisory committees, Research Funding; AstraZeneca: Research Funding. Habermann:Lilly: Other: Data Monitoring Committee. Nowakowski:Segen: Consultancy; Curis: Consultancy, Research Funding; Celgene Corporation: Consultancy, Research Funding; Fate Therapeutics: Consultancy; Bantam Pharmaceutical, LLC: Consultancy; Constellation Pharmaceuticals: Consultancy; MEI Pharma: Consultancy; Zai Laboratory: Consultancy; Incyte Corporation: Consultancy; Selvita Inc: Consultancy; Debiopharm: Consultancy; F. Hoffmann-La Roche Limited: Consultancy; MorphoSys AG: Consultancy, Research Funding; Daiichi Sankyo: Consultancy; Karyopharm Therapeutics: Consultancy; Ryvu Therapeutics: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding; AbbVie Inc.: Consultancy; ADC Therapeutics: Consultancy; Genentech: Consultancy; Blueprint Medicines Corporation: Consultancy; TG Therapeutics Inc: Consultancy; Kymera Therapeutics: Consultancy. Cerhan:BMS: Research Funding; Protagonist Therapeutics: Other: SMC; GenMab: Research Funding; Genentech: Research Funding. Gandhi:Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Novak:Bristol Myers Squibb: Research Funding.

Subtype-Specific Mechanisms of Treatment Resistance and Relapse in Diffuse Large B Cell Lymphoma (DLBCL)

View Online

Abstract

Details

Metrics